NEWS
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety and efficacy. The trial results indicated a median progression-free survival (PFS) of 14.4 months in patients with ≥4 HLA matches, compared to 2.8 months for those with ≤3 matches. CB-010 was well tolerated with no Grade 3 or higher cytokine release syndrome or graft-versus-host disease observed. Caribou plans to enroll ~20 additional patients to confirm these findings, with initial data expected in H1 2025. A pivotal Phase 3 trial is anticipated to start in H2 2025, pending confirmation of improved outcomes.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2537Followers
107Following
27KVisitors
Follow